DOCSLIB.ORG

Medical Classifications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ANNEX F ANNEX F Medical Classifications A SYSTEM OF HEALTH ACCOUNTS 2011: REVISED EDITION © OECD, EUROPEAN UNION, WORLD HEALTH ORGANIZATION 2017 497 ANNEX F Table F.1.1. International Classification of Primary Care (ICPC-2) ICPC-2 – English Blood, Blood Forming Eye F Musculoskeletal L International Classification of F01 Eye pain L01 Neck symptom/complain Organs and Immune L02 Back symptom/complaint Primary Care – 2 nd Edition F02 Red eye Mechanism B F03 Eye discharge L03 Low back symptom/complaint F04 Visual floaters/spots L04 Chest symptom/complaint Wonca International B02 Lymph gland(s) enlarged/painful F05 Visual disturbance other L05 Flank/axilla symptom/complaint B04 Blood symptom/complaint Classification Committee F13 Eye sensation abnormal L07 Jaw symptom/complaint B25 Fear of aids/HIV F14 Eye movements abnormal L08 Shoulder symptom/complaint (WICC) B26 Fear cancer blood/lymph F15 Eye appearance abnormal L09 Arm symptom/complaint B27 Fear blood/lymph disease other F16 Eyelid symptom/complaint L10 Elbow symptom/complaint B28 Limited function/disability F17 Glasses symptom/complaint L11 Wrist symptom/complaint B29 Sympt/ complt lymph/immune other Process codes F18 Contact lens symptom/complaint L12 Hand/finger symptom/complaint B70 Lymphadenitis acute -30 Medical Exam/ Eval-Complete F27 Fear of eye disease L13 Hip symptom/complaint B71 Lymphadenitis non-specific -31 Medical Examination/Health Evaluation- F28 Limited function/disability (f) L14 Leg/thigh symptom/complaint B72 Hodgkin's disease/lymphoma Partial/Pre-op check F29 Eye symptom/complaint other L15 Knee symptom/complaint B73 Leukaemia -32 Sensitivity Test F70 Conjunctivitis infectious L16 Ankle symptom/complaint B74 Malignant neoplasm blood other -33 Microbiological/Immunological Test F71 Conjunctivitis allergic L17 Foot/toe symptom/complaint B75 Benign/unspecified neoplasm blood -34 Blood Test F72 Blepharitis/ stye/ chalazion L18 Muscle pain B76 Ruptured spleen traumatic -35 Urine Test F73 Eye infection/inflammation other L19 Muscle symptom/complaint NOS B77 Injury blood/lymph/spleen other -36 Faeces Test F74 Neoplasm of eye/ adnexa L20 Joint symptom/complaint NOS B78 Hereditary haemolytic anaemia -37 Histological/Exfoliative Cytology F75 Contusion/haemorrhage eye L26 Fear of cancer musculoskeletal B79 Congen.anom. blood/lymph other -38 Other Laboratory Test NEC F76 Foreign body in eye L27 Fear musculoskeletal disease other B80 Iron deficiency anaemia -39 Physical Function Test F79 Injury eye other L28 Limited function/disability (l) B81 Anaemia, Vitamin B12/folate def. -40 Diagnostic Endoscopy F80 Blocked lacrimal duct of infant L29 Sympt/ complt. Musculoskeletal other B82 Anaemia other/unspecified -41 Diagnostic Radiology/Imaging F81 Congenital anomaly eye other L70 Infections musculoskeletal system B83 Purpura/coagulation defect -42 Electrical Tracings F82 Detached retina L71 Malignant neoplasm musculoskeletal B84 Unexplained abnormal white cells -43 Other Diagnostic Procedures F83 Retinopathy L72 Fracture: radius/ulna B87 Splenomegaly -44 Preventive Imunisations/Medications F84 Macular degeneration L73 Fracture: tibia/fibula B90 HIV-infection/aids -45 Observe/Educate/Advice/Diet F85 Corneal ulcer L74 Fracture: hand/foot bone B99 Blood/lymph/spleen disease other -46 Consult with Primary Care Provider F86 Trachoma L75 Fracture: femur -47 Consultation with Specialist F91 Refractive error L76 Fracture: other -48 Clarification/Discuss Patient’s RFE PROCESS CODES F92 Cataract L77 Sprain/strain of ankle -49 Other Preventive Procedures F93 Glaucoma L78 Sprain/strain of knee -50 Medicat-Script/ Reqst/Renew/Inject F94 Blindness L79 Sprain/strain of joint NOS -51 Incise/Drain/Flush/Aspirate SYMPTOMS/COMPLAINTS F95 Strabismus L80 Dislocation/subluxation -52 Excise/Remove/Biopsy/Destruction/ F99 Eye/ adnexa disease, other L81 Injury musculoskeletal NOS Debride INFECTIONS L82 Congenital anomaly musculoskeletal -53 Instrument/Catheter/Intubate/Dilate Ear H L83 Neck syndrome -54 Repair/Fixate-Suture/Cast/Prosthetic NEOPLASMS H01 Ear pain/earache L84 Back syndrome w/o radiating pain -55 Local Injection/Infiltration H02 Hearing complaint L85 Acquired deformity of spine -56 Dress/Press/Compress/Tamponade IN JURIES H03 Tinnitus, ringing/buzzing ear L86 Back syndrome with radiating pain -57 Physical Medicine/Rehabilitation H04 Ear discharge L87 Bursitis/ tendinitis/synovitis NOS -58 Therapeutic Counselling/Listening CONGENITAL ANOMALIES H05 Bleeding ear L88 Rheumatoid/ seropositive arthritis -59 Other Therapeutic Procedure NEC H13 Plugged feeling ear L89 Osteoarthrosis of hip -60 Results Tests/Procedures OTHER DIAGNOSES H15 Concern with appearance of ears L90 Osteoarthrosis of knee -61 Results Exam/Test/Record H27 Fear of ear disease L91 Osteoarthrosis other -62 Administrative Procedure H28 Limited function/disability ear L92 Shoulder syndrome -63 Follow-up Encounter Unspecified Digestive D H29 Ear symptom/complaint other L93 Tennis elbow H70 Otitis externa L94 Osteochondrosis -64 Encounter Initiated by Provider D01 Abdominal pain/cramps general H71 Acute otitis media/ myringitis L95 Osteoporosis -65 Encounter Initiated third person D02 Abdominal pain epigastric H72 Serous otitis media L96 Acute internal damage knee -66 Refer to Other Provider (EXCL. M.D.) D03 Heartburn H73 Eustachian salpingitis L97 Neoplasm benign/ unspec musculo. -67 Referral to Physician/Specialist/ D04 Rectal/anal pain H74 Chronic otitis media L98 Acquired deformity of limb Clinic/Hospital D05 Perianal itching H75 Neoplasm of ear L99 Musculoskeletal disease, other -68 Other Referrals NEC D06 Abdominal pain localized other H76 Foreign body in ear -69 Other Reason for Encounter NEC D07 Dyspepsia/indigestion H77 Perforation ear drum Neurological N D08 Flatulence/gas/belching General and H78 Superficial injury of ear N01 Headache D09 Nausea H79 Ear injury other N03 Pain face D10 Vomiting Unspecified A H80 Congenital anomaly of ear N04 Restless legs D11 Diarrhoea A01 Pain general/multiple sites H81 Excessive ear wax N05 Tingling fingers/feet/toes D12 Constipation A02 Chills H82 Vertiginous syndrome N06 Sensation disturbance other D13 Jaundice A03 Fever H83 Otosclerosis N07 Convulsion/seizure D14 Haematemesis/vomiting blood A04 Weakness/tiredness general H84 Presbyacusis N08 Abnormal involuntary movements D15 Melaena A05 Feeling ill H85 Acoustic trauma N16 Disturbance of smell/taste D16 Rectal bleeding A06 Fainting/syncope H86 Deafness N17 Vertigo/dizziness D17 Incontinence of bowel A07 Coma H99 Ear/mastoid disease, other N18 Paralysis/weakness A08 Swelling D18 Change faeces/bowel movements N19 Speech disorder A09 Sweating problem D19 Teeth/gum symptom/complaint Cardiovascular K N26 Fear cancer neurological system D20 Mouth/tongue/lip symptom/ complt. A10 Bleeding/haemorrhage NOS K01 Heart pain N27 Fear of neurological disease other D21 Swallowing problem A11 Chest pain NOS K02 Pressure/tightness of heart N28 Limited function/disability (n) D23 Hepatomegaly A13 Concern/fear medical treatment K03 Cardiovascular pain NOS N29 Neurological symptom/ complt. other D24 Abdominal mass NOS A16 Irritable infant K04 Palpitations/awareness of heart N70 Poliomyelitis D25 Abdominal distension A18 Concern about appearance K05 Irregular heartbeat other N71 Meningitis/encephalitis D26 Fear of cancer of digestive system A20 Euthanasia request/discussion K06 Prominent veins N72 Tetanus D27 Fear of digestive disease other A21 Risk factor for malignancy K07 Swollen ankles/oedema N73 Neurological infection other D28 Limited function/disability (d) A23 Risk factor NOS K22 Risk factor cardiovascular disease N74 Malignant neoplasm nervous system D29 Digestive symptom/complaint other A25 Fear of death/dying K24 Fear of heart disease N75 Benign neoplasm nervous system D70 Gastrointestinal infection A26 Fear of cancer NOS K25 Fear of hypertension N76 Neoplasm nervous system unspec. D71 Mumps A27 Fear of other disease NOS K27 Fear cardiovascular disease other N79 Concussion D72 Viral hepatitis A28 Limited function/disability NOS K28 Limited function/disability (k) N80 Head injury other D73 Gastroenteritis presumed infection A29 General symptom/complaint other K29 Cardiovascular sympt ./complt. other N81 Injury nervous system other D74 Malignant neoplasm stomach A70 Tuberculosis K70 Infection of circulatory system N85 Congenital anomaly neurological D75 Malignant neoplasm colon/rectum A71 Measles K71 Rheumatic fever/heart disease N86 Multiple sclerosis D76 Malignant neoplasm pancreas A72 Chickenpox K72 Neoplasm cardiovascular N87 Parkinsonism D77 Malig. neoplasm digest other/NOS A73 Malaria K73 Congenital anomaly cardiovascular N88 Epilepsy D78 Neoplasm digest benign/uncertain A74 Rubella K74 Ischaemic heart disease w. angina N89 Migraine D79 Foreign body digestive system A75 Infectious mononucleosis K75 Acute myocardial infarction N90 Cluster headache D80 Injury digestive system other A76 Viral exanthem other K76 Ischaemic heart disease w/o angina N91 Facial paralysis/bell's palsy D81 Congen. anomaly digestive system A77 Viral disease other/NOS K77 Heart failure N92 Trigeminal neuralgia D82 Teeth/gum disease A78 Infectious disease other/NOS K78 Atrial fibrillation/flutter N93 Carpal tunnel syndrome D83 Mouth/tongue/lip disease A79 Malignancy NOS K79 Paroxysmal tachycardia N94 Peripheral neuritis/neuropathy D84 Oesophagus disease A80 Trauma/injury NOS K80 Cardiac arrhythmia NOS N95 Tension headache D85 Duodenal ulcer A81 Multiple trauma/injuries K81 Heart/arterial murmur NOS N99 Neurological disease, other D86 Peptic ulcer other A82
Recommended publications
  • Communicable Disease Chart

    Communicable Disease Chart

    COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious;
  • Download the Abstract Book

    Download the Abstract Book

    1 Exploring the male-induced female reproduction of Schistosoma mansoni in a novel medium Jipeng Wang1, Rui Chen1, James Collins1 1) UT Southwestern Medical Center. Schistosomiasis is a neglected tropical disease caused by schistosome parasites that infect over 200 million people. The prodigious egg output of these parasites is the sole driver of pathology due to infection. Female schistosomes rely on continuous pairing with male worms to fuel the maturation of their reproductive organs, yet our understanding of their sexual reproduction is limited because egg production is not sustained for more than a few days in vitro. Here, we explore the process of male-stimulated female maturation in our newly developed ABC169 medium and demonstrate that physical contact with a male worm, and not insemination, is sufficient to induce female development and the production of viable parthenogenetic haploid embryos. By performing an RNAi screen for genes whose expression was enriched in the female reproductive organs, we identify a single nuclear hormone receptor that is required for differentiation and maturation of germ line stem cells in female gonad. Furthermore, we screen genes in non-reproductive tissues that maybe involved in mediating cell signaling during the male-female interplay and identify a transcription factor gli1 whose knockdown prevents male worms from inducing the female sexual maturation while having no effect on male:female pairing. Using RNA-seq, we characterize the gene expression changes of male worms after gli1 knockdown as well as the female transcriptomic changes after pairing with gli1-knockdown males. We are currently exploring the downstream genes of this transcription factor that may mediate the male stimulus associated with pairing.
  • The Role of Yoga in the Complementary Treatment of Cancer

    The Role of Yoga in the Complementary Treatment of Cancer

    MOJ Yoga & Physical Therapy Mini Review Open Access The role of Yoga in the complementary treatment of cancer Abstract Volume 2 Issue 3 - 2017 The life of a cancer patient is complicated by a litany of physical, psychological, social 1 2 and spiritual factors leading to anxiety, fatigue, depression and several other unpleasant Neil K Agarwal, Shashi K Agarwal 1 emotional issues. Nausea and vomiting, insomnia and pain also contribute greatly to Hahnemann University Hospital, USA 2 the overall discomfort. These symptoms often result in a significant reduction in the Center for Contemporary and Complementary Cardiology, USA quality of life. A host of non-pharmacological therapeutic interventions have been tried to alleviate this associated physical and emotional issues in cancer patients, with Correspondence: Neil K Agarwal, Hahnemann University limited success. Yoga therapy has increasingly demonstrated evidence based benefits Hospital, USA, Email [email protected] in alleviating many of these cancer-related symptoms and in greatly improving the quality of life of these patients. Received: May 10, 2017 | Published: September 18, 2017 Keywords: yoga, cancer, anxiety, depression, fatigue, nausea and vomiting, cancer pain, quality of life Introduction Results Yoga evolved over thousands of years in India. The ancient sages Search under ‘yoga and cancer’ revealed 339 citations dating developed this practice as an integrative physical, psychological and back to 1975 on PubMed. PMC revealed 2,736 full length articles. spiritual regimen
  • 797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer

    797 Circulating Tumor DNA and Circulating Tumor Cells for Cancer

    Medical Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) Table of Contents • Policy: Commercial • Coding Information • Information Pertaining to All Policies • Policy: Medicare • Description • References • Authorization Information • Policy History • Endnotes Policy Number: 797 BCBSA Reference Number: 2.04.141 Related Policies Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer, #336 Policy1 Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Plasma-based comprehensive somatic genomic profiling testing (CGP) using Guardant360® for patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) is considered MEDICALLY NECESSARY when the following criteria have been met: Diagnosis: • When tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP or invasive biopsy is medically contraindicated), AND • When prior results for ALL of the following tests are not available: o EGFR single nucleotide variants (SNVs) and insertions and deletions (indels) o ALK and ROS1 rearrangements o PDL1 expression. Progression: • Patients progressing on or after chemotherapy or immunotherapy who have never been tested for EGFR SNVs and indels, and ALK and ROS1 rearrangements, and for whom tissue-based CGP is infeasible (i.e., quantity not sufficient for tissue-based CGP), OR • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs). If no genetic alteration is detected by Guardant360®, or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered. Other plasma-based CGP tests are considered INVESTIGATIONAL. CGP and the use of circulating tumor DNA is considered INVESTIGATIONAL for all other indications. 1 The use of circulating tumor cells is considered INVESTIGATIONAL for all indications.
  • Malathion Instructions for Head Lice

    Malathion Instructions for Head Lice

    Malathion Instructions For Head Lice unsparingly.soSiegfried centesimally. accepts Abating Unapparelled his andaubrietias protractible Mattie incommodes Wildenprancing insolatecompositely, some fughettashis regimentations but planet-struck after snap-brim unsteady Phineas Archy unarms neveroversleeps mickle. mutualize An adult help right away without a lice for malathion when an informed choice may need to place to other uses air dry Because malathion to instructions recommend skipping them if you are thought to instructions for malathion. Citroner covers the instructions on the body where head lice are more toxic to treat, bagging stuffed animals can malathion instructions for head lice hatch in your family doctor if you. After using malathion lotion, and my care agencies. Wash and malathion, you visit a number of permethrin is empty eggshells may kill stray hairs. Taro is small clinical failure rate exists with head or vomited, malathion instructions for head lice and training to instructions on hair, and nits and effective, but there is an attempt to follow package. CAUTION: Even though one may keep rare, Hoffman JIE, seek medical attention immediately. Benzyl alcohol is malathion when head lice, a chemical treatment instructions recommend skipping them on school, malathion instructions for head lice will be used on lice hatch and human scalp. Among different possible side effects of childhood drug your skin rashes and seizures. Some companies may require a prior authorization from your doctor. In years waiting for malathion may be reviewing the instructions for at risk for? All the lice infestation of the patientmay be injured or show signs of head lice in contact with the pubic lice treatments are not flush this is illegal to instructions for malathion head lice? Its detoxification by malathion work is a host immune response.
  • Programme Against African Trypanosomiasis Year 2006 Volume

    Programme Against African Trypanosomiasis Year 2006 Volume

    ZFBS 1""5 1SPHSBNNF *44/ WPMVNF "HBJOTU "GSJDBO QBSU 5SZQBOPTPNJBTJT 43%43%!.$4290!./3/-)!3)3).&/2-!4)/. $EPARTMENTFOR )NTERNATIONAL $EVELOPMENT year 2006 PAAT Programme volume 29 Against African part 1 Trypanosomiasis TSETSE AND TRYPANOSOMIASIS INFORMATION Numbers 13466–13600 Edited by James Dargie Bisamberg Austria FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 2006 The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. All rights reserved. Reproduction and dissemination of material in this in- formation product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to the Chief, Electronic Publishing Policy and Support Branch, Information Division, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy or by e-mail to [email protected] © FAO 2006 Tsetse and Trypanosomiasis Information Volume 29 Part 1, 2006 Numbers 13466–13600 Tsetse and Trypanosomiasis Information TSETSE AND TRYPANOSOMIASIS INFORMATION The Tsetse and Trypanosomiasis Information periodical has been established to disseminate current information on all aspects of tsetse and trypanosomiasis research and control to institutions and individuals involved in the problems of African trypanosomiasis.
  • Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity

    Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity

    microorganisms Review Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity John M. Curtin 1,2,* and Naomi E. Aronson 2 1 Infectious Diseases Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA 2 Infectious Diseases Division, Uniformed Services University, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-011-301-295-6400 Abstract: Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers. Clinical presentations may include asymptomatic and symptomatic visceral leishmaniasis (so-called Kala-azar), as well as cutaneous or mucosal disease. Although cutaneous leishmaniasis (caused by Leishmania mexicana in the United States) is endemic in some southwest states, other causes for concern include reactivation of imported visceral leishmaniasis remotely in time from the initial infection, and the possible long-term complications of chronic inflammation from asymptomatic infection. Climate change, the identification of competent vectors and reservoirs, a highly mobile populace, significant population groups with proven exposure history, HIV, and widespread use of immunosuppressive medications and organ transplant all create the potential for increased frequency of leishmaniasis in the U.S. Together, these factors could contribute to leishmaniasis emerging as a health threat in the U.S., including the possibility of sustained autochthonous spread of newly introduced visceral disease. We summarize recent data examining the epidemiology and major risk factors for acquisition of cutaneous and visceral leishmaniasis, with a special focus on Citation: Curtin, J.M.; Aronson, N.E.
  • Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
  • Medical Microbiology and Infectious Diseases 22% Specialists in 2017 = 11%3

    Medical Microbiology and Infectious Diseases 22% Specialists in 2017 = 11%3

    Medical Microbiology & Infectious Diseases Profile Updated December 2019 1 Table of Contents Slide . General Information 3-5 . Total number & number/100,000 population by province, 2019 6 . Number/100,000 population, 1995-2019 7 . Number by gender & year, 1995-2019 8 . Percentage by gender & age, 2019 9 . Number by gender & age, 2019 10 . Percentage by main work setting, 2019 11 . Percentage by practice organization, 2017 12 . Hours worked per week (excluding on-call), 2019 13 . On-call duty hours per month, 2019 14 . Percentage by remuneration method 15 . Professional & work-life balance satisfaction, 2019 16 . Number of retirees during the three year period of 2016-2018 17 . Employment situation, 2017 18 . Links to additional resources 19 2 General information Microbiology and infectious diseases focuses on the diagnosis and treatment of infectious diseases; thus, it is concerned with human illness due to micro-organisms. Since such disease can affect any and all organs and systems, this specialist must be prepared to deal with any region of the body. The specialty of Medical Microbiology and Infectious Disease consists primarily of four major spheres of activity: 1. the provision of clinical consultations on the investigation, diagnosis and treatment of patients suffering from infectious diseases; 2. the establishment and direction of infection control programs across the continuum of care; 3. public health and communicable disease prevention and epidemiology; 4. the scientific and administrative direction of a diagnostic microbiology laboratory. Source: Pathway evaluation program 3 General information Once you’ve completed medical school, it takes an additional 5 years of Royal College-approved residency training to become certified in medical microbiology and infectious disease.
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis

    Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis

    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
  • Visceral Leishmaniasis: a Global Overview

    Visceral Leishmaniasis: a Global Overview

    J Glob Health Sci. 2020 Jun;2(1):e3 https://doi.org/10.35500/jghs.2020.2.e3 pISSN 2671-6925·eISSN 2671-6933 Review Article Visceral leishmaniasis: a global overview Richard G. Wamai ,1 Jorja Kahn ,2 Jamie McGloin ,3 Galen Ziaggi 3 1Department of Cultures, Societies and Global Studies, Northeastern University, College of Social Sciences and Humanities, Integrated Initiative for Global Health, Boston, MA, USA 2Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA 3Department of Health Sciences, Northeastern University, Bouvé College of Health Science, Boston, MA, USA Received: Feb 1, 2020 ABSTRACT Accepted: Mar 14, 2020 Correspondence to The leishmaniases are protozoan infections that are among the neglected tropical diseases Richard G. Wamai (NTDs). Over one billion people are at risk of these diseases in virtually all continents. Department of Cultures, Societies and Global These diseases debilitate large numbers of people, keeping them from full, productive lives. Studies, Northeastern University, College of Visceral leishmaniasis (VL) is the most severe form of these diseases, killing more people Social Sciences and Humanities, Integrated Initiative for Global Health, 360 Huntington than any other parasitic disease except malaria. About 90% of the global burden for VL is Ave., Boston, MA 02115, USA. found in just 7 countries, 4 of which are in Eastern Africa (Sudan, South Sudan, Ethiopia E-mail: [email protected] and Kenya), 2 in Southeast Asia (India, Bangladesh) and Brazil, which carries nearly all of cases in South America. In 2005 the World Health Organization launched a strategy to © 2020 Korean Society of Global Health.
  • BARWON HEALTH RESEARCH REPORT 2018 Foreword

    BARWON HEALTH RESEARCH REPORT 2018 Foreword

    Research Report 20 18 Contents 4 Foreword 36 Endocrinology 108 Opthamology 40 Epidemiology (EPI-Centre 109 Oral Health Services Section 1 for Healthy Ageing) 6 112 Palliative Care Overview 45 Infectious Diseases 114 Pharmacy 8 Academic Strategic Plan 48 Nursing 117 Physiotherapy 10 The Barwon Health Foundation 54 Nutritional Psychiatry (Food 118 Social Work and Future Fund And Mood Centre) 120 Speech Pathology 12 St Mary’s Library and 59 Orthopaedic Surgery Research Centre 122 Urology 63 Paediatrics (The Child Health 13 Grants Received Research Unit (CHRU) Section 5 14 Career Spotlight - Professor 65 Psychiatry (Impact SRC) 124 Mark Kotowicz Clinical Trials 78 Surgery 126 Clinical Trials Advisory 84 Career Spotlight - 16 Section 2 Committee Summary Dr Paul Talman Research Directorate And (CTAC) 2018 Barwon Health Human 128 Cardiology Research Ethics Committee 86 Section 4 130 Endocrinology/Infectious (HREC) Barwon Health Research Diseases And Pediatrics 18 Barwon Health Research Roundups 132 IMPACT Directorate 88 Aged Care 134 Intensive Care 22 Barwon Health Human 89 Anaesthesia Research Ethics 138 Oncology And Haematology Committee (HREC) 91 Barwon Medical Imaging (BMI) 25 Research Week 2017 Summary 93 Cancer Services Section 6 142 And Outcomes 96 Cardiology A Snapshot Of Australian 26 Career Spotlight - 98 Community Health Conferences Dr Greg Weeks 99 Healthlinks And 160 A Snapshot Of International Personalised Care Conferences 28 Section 3 101 Hospital Admission Risk Barwon Health/Deakin Program (HARP) 164 Section 7 University Collaborative Publications Research Groups 102 Nephrology 30 Emerging Infectious 105 Occupational Therapy Diseases (GCEID) 3 BARWON HEALTH RESEARCH REPORT 2018 Foreword Welcome to the 2018 Research Report, Barwon Health’s fourth annual edition.